Search research articles
Contact Us
Filters
Showing results (61-70 of 103) with videos related to
Page
of 11
Sort By:
Expert Review of Hematology
|
September 23, 2021
Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies
Kamlesh Bisht, Brian Walker, Shaji K Kumar, et al.
Haematologica
|
April 23, 2026
Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab
Guido Lancman, Dahniel Sastow, Minira Aslanova, et al.
American Journal of Hematology
|
March 27, 2025
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis
Joshua Richter, Ajay Nooka, Paula Rodríguez-Otero, et al.
Blood Cancer Journal
|
September 19, 2023
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, et al.
Brain Communications
|
December 19, 2025
Transcranial direct current stimulation over the frontal eye field has no effect on visual search performance
Charline Peylo, Constanze Albrecht, Ruth Gerlinde Homann, et al.
Journal of Hematology & Oncology
|
July 16, 2020
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
Bo Wang, Oliver Van Oekelen, Tarek H Mouhieddine, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 25, 2020
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
Bo Wang, Oliver Van Oekelen, Tarek H Mouhieddine, et al.
Bone Marrow Transplantation
|
October 19, 2022
Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support
Tarek H Mouhieddine, Erin Moshier, Santiago Thibaud, et al.
Bone Marrow Transplantation
|
May 3, 2025
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma
Darren Pan, Tarek H Mouhieddine, Tianxiang Sheng, et al.
Future Oncology (London, England)
|
October 9, 2023
<i>In</i>-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma
Robert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 103) with videos related to
Sort By:
Page
of 11
Expert Review of Hematology
|
September 23, 2021
Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies
Kamlesh Bisht, Brian Walker, Shaji K Kumar, et al.
Haematologica
|
April 23, 2026
Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab
Guido Lancman, Dahniel Sastow, Minira Aslanova, et al.
American Journal of Hematology
|
March 27, 2025
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis
Joshua Richter, Ajay Nooka, Paula Rodríguez-Otero, et al.
Blood Cancer Journal
|
September 19, 2023
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, et al.
Brain Communications
|
December 19, 2025
Transcranial direct current stimulation over the frontal eye field has no effect on visual search performance
Charline Peylo, Constanze Albrecht, Ruth Gerlinde Homann, et al.
Journal of Hematology & Oncology
|
July 16, 2020
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
Bo Wang, Oliver Van Oekelen, Tarek H Mouhieddine, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 25, 2020
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
Bo Wang, Oliver Van Oekelen, Tarek H Mouhieddine, et al.
Bone Marrow Transplantation
|
October 19, 2022
Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support
Tarek H Mouhieddine, Erin Moshier, Santiago Thibaud, et al.
Bone Marrow Transplantation
|
May 3, 2025
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma
Darren Pan, Tarek H Mouhieddine, Tianxiang Sheng, et al.
Future Oncology (London, England)
|
October 9, 2023
<i>In</i>-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma
Robert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, et al.
Page
of 11